TH96041B - Cancer treatments and how they are involved - Google Patents
Cancer treatments and how they are involvedInfo
- Publication number
- TH96041B TH96041B TH1501004650A TH1501004650A TH96041B TH 96041 B TH96041 B TH 96041B TH 1501004650 A TH1501004650 A TH 1501004650A TH 1501004650 A TH1501004650 A TH 1501004650A TH 96041 B TH96041 B TH 96041B
- Authority
- TH
- Thailand
- Prior art keywords
- bone marrow
- cancer
- quinolin
- fluoro
- amino
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract 6
- 239000000126 substance Substances 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 150000004001 inositols Chemical class 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 2
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 208000000649 small cell carcinoma Diseases 0.000 abstract 1
Abstract
ให้วิธีรักษามะเร็งโดยใช้ 4 - อะมิโน -5-ฟลูออโร-3-[6-(4-เมธิลพิเพอราซิน - 1-อิล) -1H- เบนซิมิตาซอล-2-อิล] ควินอลิน-2(1H) - โอน โดยเฉพาะ, วิธีให้ผลสำหรับการรักษาเนื้องอกชนิดแข็ง หรือมะเร็งเม็ดเลือดขาว, ซึ่งรวมถึงต่อมลูกหมาก, บริเวณลำไส้ใหญ่และไส้ตรง, เต้านม, มัลทิเพิล ไมอีโลมา, ตับอ่อน, มะเร็งเซลล์ขนาดเล็ก, มะเร็งไขกระดูกเฉียบพลัน, มะเร็งไขกระดูกเรื้อรัง, หรือ โรคเนื้องอกไขกระดูก ที่ยังให้ไว้คือวิธีวัดปริมาณของ 4 - อะมิโน-5-ฟลูออโร-3-[6- (4-เมธิล พิเพอราซิน-1-อิล) -1H- เบนซิมิตาซอล-2-อิล] ควินอลิน-2-(1H)- โอน และการวิเคราะห์โครงร่าง เมแทบอลิคของสารเหล่านั้น Provides a cancer treatment method using 4 - amino -5-fluoro-3-[6-(4-methylpiperacin - 1-yl) -1H- benzimitazoan. [L-2-yl] Quinolin-2(1H) - A specific, effective method for the treatment of solid tumors. or leukemia, which includes prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute bone marrow cancer, chronic bone marrow cancer, or bone marrow tumor. Also provided is a method for measuring the amount of 4 - amino-5-fluoro-3-[6- (4-methyl piperacin-1-yl) -1H- benzene. mitasol-2-yl] quinolin-2-(1H)-one and skeletal analysis Metabolism of those substances
Claims (2)
Publications (3)
| Publication Number | Publication Date |
|---|---|
| TH96041B true TH96041B (en) | 2009-06-18 |
| TH1501004650A TH1501004650A (en) | 2017-08-24 |
| TH166428A TH166428A (en) | 2017-08-24 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amelio et al. | Liquid biopsies and cancer omics | |
| Mader et al. | Liquid biopsy: current status and future perspectives | |
| Mu et al. | Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer | |
| Doherty et al. | Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes | |
| Aggarwal et al. | Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy | |
| Rossi et al. | CTCs 2020: great expectations or unreasonable dreams | |
| Longuespée et al. | Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges | |
| Bitting et al. | Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration–resistant prostate cancer | |
| Massard et al. | RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study | |
| Houshmand et al. | The role of dual and multiple time point imaging of FDG uptake in both normal and disease states | |
| Sugihara et al. | A new look at drugs targeting malignant melanoma—an application for mass spectrometry imaging | |
| Liang et al. | Exploring type II microcalcifications in benign and premalignant breast lesions by shell-isolated nanoparticle-enhanced Raman spectroscopy (SHINERS) | |
| Hussain et al. | Tumor-educated platelets in lung cancer | |
| Dubbelman et al. | Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors | |
| Shen et al. | Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer | |
| Vinayanuwattikun et al. | Feasibility technique of low-passage in vitro drug sensitivity testing of malignant pleural effusion from advanced-stage non-small cell lung cancer for prediction of clinical outcome | |
| Łaczmańska et al. | Personalised medicine in lung cancer | |
| Dieci et al. | Quantification of residual risk of relapse in breast cancer patients optimally treated | |
| Appels et al. | Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer | |
| Oh et al. | Discovery of 4H-chromeno [2, 3-d] pyrimidin-4-one derivatives as senescence inducers and their senescence-associated antiproliferative activities on cancer cells using advanced phenotypic assay | |
| Boshuizen et al. | Circulating tumor cells in non-small cell lung carcinoma | |
| Pickl et al. | Predictive markers in early research and companion diagnostic developments in oncology | |
| Hattori | Role of circulating tumor cells in breast cancer | |
| WO2017053763A3 (en) | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) | |
| Genne et al. | Abstract 1875A: Preclinical proof of concept for the first Nanocyclix TKI-PET radiotracer targeting activated EGFR positive lung tumors |